VU 0364439 is primarily utilized in neuroscience research as a potent and selective positive allosteric modulator (PAM) of the metabotropic glutamate receptor subtype 4 (mGlu4). Its application is significant in studying the role of mGlu4 receptors in various neurological disorders. Researchers employ it to investigate potential therapeutic strategies for conditions such as Parkinson's disease, where modulation of mGlu4 receptors may help alleviate motor symptoms. Additionally, it is used in preclinical studies to explore its effects on anxiety, depression, and other central nervous system disorders, providing insights into the receptor's function and potential drug development pathways.